Avoro Capital Advisors LLC Has $730.18 Million Holdings in argenex SE $ARGX

Avoro Capital Advisors LLC lessened its position in argenex SE (NASDAQ:ARGX) by 15.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 990,000 shares of the company’s stock after selling 185,000 shares during the period. argenex comprises 9.4% of Avoro Capital Advisors LLC’s portfolio, making the stock its 4th largest holding. Avoro Capital Advisors LLC owned about 1.61% of argenex worth $730,184,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ARGX. Wellington Management Group LLP lifted its position in argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after acquiring an additional 324,653 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in shares of argenex in the 3rd quarter worth $358,000. FORA Capital LLC purchased a new position in shares of argenex in the third quarter worth $456,000. Glenmede Investment Management LP bought a new position in shares of argenex during the third quarter valued at $490,000. Finally, Pathstone Holdings LLC lifted its holdings in shares of argenex by 3.4% during the third quarter. Pathstone Holdings LLC now owns 2,417 shares of the company’s stock valued at $1,783,000 after purchasing an additional 80 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ARGX shares. JPMorgan Chase & Co. lifted their price objective on argenex from $925.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Monday, December 8th. Stifel Nicolaus upped their target price on shares of argenex from $1,028.00 to $1,248.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. HC Wainwright raised their price target on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a report on Friday, February 27th. Citigroup reduced their price target on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Finally, Guggenheim decreased their price objective on shares of argenex from $1,160.00 to $1,120.00 and set a “buy” rating for the company in a report on Friday, February 27th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $999.22.

argenex Stock Down 1.2%

ARGX stock opened at $700.45 on Friday. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62. The stock has a market cap of $43.34 billion, a P/E ratio of 35.88, a PEG ratio of 1.17 and a beta of 0.38. The business’s 50-day moving average price is $804.00 and its 200-day moving average price is $815.97.

argenex (NASDAQ:ARGX) last released its earnings results on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.05 by $1.97. argenex had a net margin of 30.42% and a return on equity of 38.51%. The company had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. On average, equities research analysts expect that argenex SE will post 3.13 earnings per share for the current fiscal year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.